Our results demonstrated that detectable ctDNA mutations, a mean VAF value ≥ 4.94%, and PCLO mutations were strongly associated with shorter OS and PFS in the newly diagnosed DLBCL patients. The gene discussed is PCLO; the disease is diffuse large B-cell lymphoma.